{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:24:17Z","timestamp":1761845057747},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1684\/bdc.2011.1441","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:01:59Z","timestamp":1565726519000},"page":"S47-S59","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S","title":["Gestion des effets secondaires des th\u00e9rapies cibl\u00e9es dans le cancer du rein : effets secondaires endocriniens et troubles m\u00e9taboliques"],"prefix":"10.1016","volume":"98","author":[{"given":"Philippe","family":"Caron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwena\u00eblle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2011.1441_bib0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0889-8529(05)70186-9","article-title":"Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease","volume":"30","author":"Ross","year":"2001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1684\/bdc.2011.1441_bib0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1634\/theoncologist.2008-0120","article-title":"Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies","volume":"13","author":"Hutson","year":"2008","journal-title":"Oncologist"},{"key":"10.1684\/bdc.2011.1441_bib0020","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1684\/bdc.2011.1441_bib0025","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1684\/bdc.2011.1441_bib0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2011.1441_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1441_bib0040","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1441_bib0045","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.17.2.253","article-title":"Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma","volume":"17","author":"Sonpavde","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1684\/bdc.2011.1441_bib0055","unstructured":"OMS. Le diab\u00e8te sucr\u00e9. Rapport d'un groupe d'\u00e9tude de l'OMS. Gen\u00e8ve, 1985 (S\u00e9rie de rapports techniques n\u00b0727)."},{"key":"10.1684\/bdc.2011.1441_bib0060","unstructured":"ANAES. Modalit\u00e9s de d\u00e9pistage et diagnostic biologique des dyslipid\u00e9mies en pr\u00e9vention primaire. 2000. www.unaformec.org\/CDRMG\/cederom_ol\/recos\/anaes\/dysli_00.pdf (acc\u00e9d\u00e9 le 14\/12\/10)."},{"key":"10.1684\/bdc.2011.1441_bib0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1684\/bdc.2011.1441_bib0070","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0075","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1441_bib0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of \u00e9verolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1684\/bdc.2011.1441_bib0085","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/COC.0b013e3181574084","article-title":"Sorafenib for metastatic renal cancer: the Princess Margaret experience","volume":"31","author":"Riechelmann","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/era.09.27","article-title":"\u00c9verolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma","volume":"9","author":"Oudard","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1684\/bdc.2011.1441_bib0100","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (\u00e9verolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1684\/bdc.2011.1441_bib0105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/SPC.0b013e32832e4681","article-title":"Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma","volume":"3","author":"Guevremont","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1684\/bdc.2011.1441_bib0110","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0115","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.bjc.6604709","article-title":"Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Billemont","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2011.1441_bib0120","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/annonc\/mdn047","article-title":"Remission of diabetes while on sunitinib treatment for renal cell carcinoma","volume":"19","author":"Templeton","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0125","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2011.1441_bib0130","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1046\/j.1365-2265.2003.01848.x","article-title":"Hypoglycaemia in a patient with a gastrointestinal stromal tumour","volume":"59","author":"Beckers","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1684\/bdc.2011.1441_bib0135","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1684\/bdc.2011.1441_bib0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115305257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:35:23Z","timestamp":1602491723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115305257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0007455115305257"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2011.1441","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}